MA45141B1 - Process for the preparation of n-(5-(3-(7-(3-fluorophenyl))-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin- 3-yl)-3-methylbutanamide - Google Patents

Process for the preparation of n-(5-(3-(7-(3-fluorophenyl))-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin- 3-yl)-3-methylbutanamide

Info

Publication number
MA45141B1
MA45141B1 MA45141A MA45141A MA45141B1 MA 45141 B1 MA45141 B1 MA 45141B1 MA 45141 A MA45141 A MA 45141A MA 45141 A MA45141 A MA 45141A MA 45141 B1 MA45141 B1 MA 45141B1
Authority
MA
Morocco
Prior art keywords
pyridin
preparation
methylbutanamide
indazol
imidazo
Prior art date
Application number
MA45141A
Other languages
French (fr)
Other versions
MA45141A (en
Inventor
Sunil Kumar Kc
Original Assignee
Biosplice Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosplice Therapeutics Inc filed Critical Biosplice Therapeutics Inc
Priority claimed from PCT/US2017/035411 external-priority patent/WO2017210407A1/en
Publication of MA45141A publication Critical patent/MA45141A/en
Publication of MA45141B1 publication Critical patent/MA45141B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé synthétique de préparation d'un composé de formule (1). L'invention concerne également des intermédiaires et des sels utiles, des formes amorphes et polymorphes du composé de formule (1). Ces composés sont utiles contre diverses maladies, notamment le cancer, la prolifération cellulaire anormale, l'angiogenèse, la maladie d'alzheimer et l'ostéoarthrite, ainsi que les maladies liées à wnt.The invention relates to a synthetic process for the preparation of a compound of formula (1). The invention also relates to useful intermediates and salts, amorphous and polymorphic forms of the compound of formula (1). These compounds are useful against various diseases, including cancer, abnormal cell proliferation, angiogenesis, Alzheimer's disease and osteoarthritis, as well as wnt-related diseases.

MA45141A 2016-06-01 2017-06-01 Process for the preparation of n-(5-(3-(7-(3-fluorophenyl))-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin- 3-yl)-3-methylbutanamide MA45141B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344170P 2016-06-01 2016-06-01
PCT/US2017/035411 WO2017210407A1 (en) 2016-06-01 2017-06-01 Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide

Publications (2)

Publication Number Publication Date
MA45141A MA45141A (en) 2019-04-10
MA45141B1 true MA45141B1 (en) 2022-12-30

Family

ID=84783663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45141A MA45141B1 (en) 2016-06-01 2017-06-01 Process for the preparation of n-(5-(3-(7-(3-fluorophenyl))-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin- 3-yl)-3-methylbutanamide

Country Status (1)

Country Link
MA (1) MA45141B1 (en)

Also Published As

Publication number Publication date
MA45141A (en) 2019-04-10

Similar Documents

Publication Publication Date Title
MD3464285T2 (en) Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
MX2020003458A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
WO2007058832A3 (en) Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
CR20200263A (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
NO20076371L (en) Process for the preparation of phenolic 4-biphenylylazetidin-2-ones
NZ741907A (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
MY200629A (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MA35452B1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors
EA201071370A1 (en) SERO-CONTAINING HETEROCYCLIC DERIVATIVES, HAVING ACTIVITY OF THE BETA SECRETASE INHIBITOR
MX361020B (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carbo xamide and salts thereof.
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
MX353461B (en) Processes for making compounds useful as inhibitors of atr kinase.
MX2012001420A (en) Pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors.
MX2016008536A (en) Fluoro-naphthyl derivatives.
WO2023073013A8 (en) Lrrk2 inhibitors
EA201171393A1 (en) 7 - ([1,2,4] TRIAZOLO [1,5α] Pyridine-6-IL) -4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-ISOHINOLINE and ITS APPLICATION
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
WO2008024151A3 (en) Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use
NO20076161L (en) Methods for preparing 4-biphenylazetidin-2-ones
MA45141B1 (en) Process for the preparation of n-(5-(3-(7-(3-fluorophenyl))-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin- 3-yl)-3-methylbutanamide